Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) – Investment analysts at Jefferies Financial Group upped their Q1 2023 EPS estimates for Supernus Pharmaceuticals in a research note issued to investors on Tuesday, February 28th. Jefferies Financial Group analyst A. Tsai now expects that the specialty pharmaceutical company will post earnings per share of $0.35 for […]